Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
Date:7/29/2009

CRANBURY, N.J., July 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce second quarter 2009 financial results after the regular close of markets on Wednesday, August 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.

Interested participants and investors may access the conference call at 5 p.m. EDT by dialing 877-591-4949 (U.S./Canada) or 719-325-4889 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4035217.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity.
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
2. Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date
3. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
4. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
5. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Amicus Therapeutics Announces Change to Board of Directors
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
10. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
11. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... a biopharmaceutical company advancing patient care in critical areas, ... 3,500,000 shares of common stock, and warrants to purchase ... at an offering price of $4.00 per share and ... exercise price of $5.00, are exercisable immediately, and expire ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ... the estimates and forecasts of the revenue and ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... , , , BETHESDA, ... ), a biopharmaceutical company developing novel, proprietary antibodies for the ... interim data from a phase 1 dose-escalation clinical study for ... treatment of solid tumors. The interim data(1) were presented at ...
... , , , ... VOLC ), a leader in the development, manufacturing and sales ... artery disease, announced today its participation in the 2009 Transcatheter Cardiovascular ... programming for TCT includes a first look at new study data, ...
... , ST. PAUL, Minn., Sept. 21 Brennen ... its XenMatrix(R) device to Davol Inc., a subsidiary of C.R. Bard, ... related assets of the hernia products business of Brennen Medical, LLC. ... for use in soft tissue repair including hernia and abdominal wall ...
Cached Biology Technology:Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 2Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 3Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 4Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 2Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 3Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 4Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 5Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 6Brennen Medical Announces Sale of XenMatrix(R) 2
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... more crucial to fundamental global issues, including health, ... Jacobs School of Engineering,s top ranked bioengineering department ... this field. The Siebel Foundation has recognized ... million endowment to fund fellowships for some of ...
... in Canada have established a new university/industry network to ... delivery systems to treat the increasing incidence of eye ... Network) has received $5 million as part of the ... funding announcement made by federal Minister of State (Science ...
... University of Michigan scientists have developed a combination ... medics and fellow soldiers in battle situations to give ... limits morphine,s dangerous side effects. They use ... the drugs into the body. The development of the ...
Cached Biology News:Siebel Foundation awards top UC San Diego bioengineering graduate students 2Siebel Foundation awards top UC San Diego bioengineering graduate students 3Siebel Foundation awards top UC San Diego bioengineering graduate students 4New research network at McMaster aims to build a better eye 2Nanoparticle-based battlefield pain treatment moves a step closer 2
... assay can detect H2O2 or peroxidase activity ... oxidizes ADHP in a 1:1 stoichiometry to ... 530-571 nm, emission at 590-600 nm). This ... one-step, homogeneous, no wash assay system. ADHP ...
...
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
... net results - with a modular approach ... management! The ChemStation Plus NDS family provides ... acquisition and data management, giving you the ... your labs needs now and that can ...
Biology Products: